자궁내막증 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Endometriosis Treatment Market Growth & Trends:

The global endometriosis treatment market size is expected to reach USD 3.52 billion by 2030, registering a CAGR of 12.25% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is attributed to the presence of a late-stage robust product pipeline, the global upsurge in cases, and several initiatives undertaken by the government and key players at national and international levels to raise disease awareness.

The growing research and development for new treatment options in space is expected to offer a lucrative opportunity for market growth in the coming years. The launch of Myovant / Pfizer's Relugolix combination tablet, ObsEva's Yselty (linzagolix), and Ferring Pharmaceuticals / Novartis' Quinagolide are among prominent drug launches in this space that are anticipated to fuel the market growth.

Rising demand for endometriosis treatment is attributed to increasing disease burden and delay in diagnosis, worsening the disease condition. In March 2021, as per WHO, approximately 10% of female reproductive population is affected by the disease worldwide. According to the article, "Impact of Endometriosis Diagnostic Delays on Healthcare Resource Utilization and Costs", a delay of three or more years in diagnosis from developing first symptom leads to increase in symptom burden and increase in healthcare cost by 50% compared with patients who were diagnosed earlier after symptom onset.

WHO, national governments, and private organizations are strategically involved in spreading awareness and educating people about endometriosis and its treatment, thereby supporting market growth. For instance, in March 2022, the Endometriosis Foundation of America hosted four weekends of the virtual program featuring patients and physicians, helping to connect endometriosis warriors and share their experiences with the disease. Moreover, in March 2022, Endometriosis U.K. also launched an eight-point action plan during the 'Endometriosis Action Month'.

Furthermore, key players are undertaking strategic initiatives such as mergers and acquisitions, collaborations, financial investments, and geographical expansion fueling the endometriosis treatment market. For instance, in November 2021, Organon and Co. announced to acquire Forendo Pharma, which will support Forendo's development of novel drugs in endometriosis like OR-6219, a phase 2 clinical candidate.

Endometriosis Treatment Market Report Highlights:

• By treatment type, the hormone therapy segment accounted for the largest share of the market in 2024 due to the high prescription rate of these drugs by physicians
• Gonadotropin-releasing hormone (GnRH) segment dominated the drug class segment in 2024 due to the high efficacy of GnRH agonists and GnRH antagonists and the increased availability of these products in the market
• In 2024, oral segment dominated the market with a 48.46% share by route of administration. It is the most common & convenient route of delivery for the majority of products in this space
• In 2024, retail pharmacy segment dominated the market by distribution channel. Moreover, hospital pharmacy is expected to demonstrate moderate growth
• North America dominated the global market in 2024 owing to increased disease incidence and high awareness among people and healthcare professionals about the condition therapies

Table of Content

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation
  • 1.1.1 Regional Scope
• 1.2 Market Definitions
  • 1.2.1 Estimates And Forecast Timeline
• 1.3 Objectives
  • 1.3.1 Objective - 1
  • 1.3.2 Objective - 2
  • 1.3.3 Objective - 3
• 1.4 Research Methodology
• 1.5 Information Procurement
  • 1.5.1 Purchased Database
  • 1.5.2 Gvr's Internal Database
  • 1.5.3 Secondary Sources
  • 1.5.4 Primary Research
  • 1.5.5 Details Of Primary Research
• 1.6 Information or Data Analysis
  • 1.6.1 Data Analysis Models
• 1.7 Market Formulation & Validation
• 1.8 Model Details
  • 1.8.1 Commodity Flow Analysis
    • 1.8.1.1 Approach 1: Commodity Flow Approach
    • 1.8.1.2 Approach 2: Country wise market estimation using bottom-up approach
• 1.9 List of Secondary Sources
• 1.10 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Treatment Type and Drug Class Segment Snapshot
• 2.3 Route of Administration and Distribution Channel Segment Snapshots
• 2.4 Competitive Landscape Snapshot

Chapter 3 Market Variables and Trends

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Related/Ancillary Market Outlook
• 3.2 Market Trends & Outlook
• 3.3 Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Rising disease burden
    • 3.3.1.2 Growing awareness toward the disease
    • 3.3.1.3 Increasing funding for research and development
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 Availability of over the counter and generic drugs
• 3.4 Business Environment Analysis
  • 3.4.1 PORTER'S Five Forces Analysis
  • 3.4.2 PESTEL Analysis
• 3.5 Pipeline Analysis (Phase 3)

Chapter 4 Endometriosis Treatment Market- Segment Analysis, by Treatment Type, 2018 - 2030 (USD Million)

• 4.1 Endometriosis Treatment Market: Treatment Type Movement Analysis
• 4.2 Endometriosis Treatment Market Estimates & Forecast, By Treatment Type (USD Million)
  • 4.2.1 Pain Medication
  • 4.2.2 Hormone Therapy

Chapter 5 Endometriosis Treatment Market- Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

• 5.1 Endometriosis Treatment Market: Drug Class Movement Analysis
• 5.2 Endometriosis Treatment Market Estimates & Forecast, By Drug Class (USD Million)
  • 5.2.1 Nsaids
  • 5.2.2 Oral Contraceptives
  • 5.2.3 Gonadotropin-Releasing Hormone
  • 5.2.4 Others

Chapter 6 Endometriosis Treatment Market- Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)

• 6.1 Endometriosis Treatment Market: Route of Administration Movement Analysis
• 6.2 Endometriosis Treatment Market Estimates & Forecast, By Route of Administration (USD Million)
  • 6.2.1 Oral
  • 6.2.2 Injectable
  • 6.2.3 Others

Chapter 7 Endometriosis Treatment Market- Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 7.1 Endometriosis Treatment Market: Distribution Channel Movement Analysis
• 7.2 Endometriosis Treatment Market Estimates & Forecast, By Distribution Channel (USD Million)
  • 7.2.1 Hospital Pharmacies
  • 7.2.2 Retail Pharmacies
  • 7.2.3 Others

Chapter 8 Endometriosis Treatment Market: Regional Estimates and Trend Analysis by Type, Drug Class, Route of Administration, and Distribution Channel

• 8.1 Endometriosis Treatment Market: Regional Outlook
• 8.2 North America
  • 8.2.1 North America Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2 U.S.
    • 8.2.2.1 Key Country Dynamics
    • 8.2.2.2 U.S. Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2.3 Competitive/Market Scenario
    • 8.2.2.4 Regulatory Framework
    • 8.2.2.5 Reimbursement Scenario
  • 8.2.3 Canada
    • 8.2.3.1 Key Country Dynamics
    • 8.2.3.2 Canada Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3.3 Competitive/Market Scenario
    • 8.2.3.4 Regulatory Framework
    • 8.2.3.5 Reimbursement Scenario
  • 8.2.4 Mexico
    • 8.2.4.1 Key Country Dynamics
    • 8.2.4.2 Mexico Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4.3 Competitive/Market Scenario
    • 8.2.4.4 Regulatory Framework
    • 8.2.4.5 Reimbursement Scenario
• 8.3 Europe
  • 8.3.1 Europe Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2 UK
    • 8.3.2.1 Key Country Dynamics
    • 8.3.2.2 UK Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2.3 Competitive/Market Scenario
    • 8.3.2.4 Regulatory Framework
    • 8.3.2.5 Reimbursement Scenario
  • 8.3.3 Germany
    • 8.3.3.1 Key Country Dynamics
    • 8.3.3.2 Germany Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3.3 Competitive/Market Scenario
    • 8.3.3.4 Regulatory Framework
    • 8.3.3.5 Reimbursement Scenario
  • 8.3.4 France
    • 8.3.4.1 Key Country Dynamics
    • 8.3.4.2 France Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4.3 Competitive/Market Scenario
    • 8.3.4.4 Regulatory Framework
    • 8.3.4.5 Reimbursement Scenario
  • 8.3.5 Italy
    • 8.3.5.1 Key Country Dynamics
    • 8.3.5.2 Italy Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5.3 Competitive/Market Scenario
    • 8.3.5.4 Regulatory Framework
    • 8.3.5.5 Reimbursement Scenario
  • 8.3.6 Spain
    • 8.3.6.1 Key Country Dynamics
    • 8.3.6.2 Spain Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6.3 Competitive/Market Scenario
    • 8.3.6.4 Regulatory Framework
    • 8.3.6.5 Reimbursement Scenario
  • 8.3.7 Denmark
    • 8.3.7.1 Key Country Dynamics
    • 8.3.7.2 Denmark Influenza Vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.7.3 Competitive/Market Scenario
    • 8.3.7.4 Regulatory Framework
    • 8.3.7.5 Reimbursement Scenario
  • 8.3.8 Sweden
    • 8.3.8.1 Key Country Dynamics
    • 8.3.8.2 Sweden Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8.3 Competitive/Market Scenario
    • 8.3.8.4 Regulatory Framework
    • 8.3.8.5 Reimbursement Scenario
  • 8.3.9 Norway
    • 8.3.9.1 Key Country Dynamics
    • 8.3.9.2 Norway Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9.3 Competitive/Market Scenario
    • 8.3.9.4 Regulatory Framework
    • 8.3.9.5 Reimbursement Scenario
  • 8.3.10 Rest Of Europe Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.4 Asia Pacific
  • 8.4.1 Asia Pacific Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2 Japan
    • 8.4.2.1 Key Country Dynamics
    • 8.4.2.2 Japan Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2.3 Competitive/Market Scenario
    • 8.4.2.4 Regulatory Framework
    • 8.4.2.5 Reimbursement Scenario
  • 8.4.3 China
    • 8.4.3.1 Key Country Dynamics
    • 8.4.3.2 China Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3.3 Competitive/Market Scenario
    • 8.4.3.4 Regulatory Framework
    • 8.4.3.5 Reimbursement Scenario
  • 8.4.4 India
    • 8.4.4.1 Key Country Dynamics
    • 8.4.4.2 India Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4.3 Competitive/Market Scenario
    • 8.4.4.4 Regulatory Framework
    • 8.4.4.5 Reimbursement Scenario
  • 8.4.5 Australia
    • 8.4.5.1 Key Country Dynamics
    • 8.4.5.2 Australia Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5.3 Competitive/Market Scenario
    • 8.4.5.4 Regulatory Framework
    • 8.4.5.5 Reimbursement Scenario
  • 8.4.6 Thailand
    • 8.4.6.1 Key Country Dynamics
    • 8.4.6.2 Thailand Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6.3 Competitive/Market Scenario
    • 8.4.6.4 Regulatory Framework
    • 8.4.6.5 Reimbursement Scenario
  • 8.4.7 South Korea
    • 8.4.7.1 Key Country Dynamics
    • 8.4.7.2 South Korea Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7.3 Competitive/Market Scenario
    • 8.4.7.4 Regulatory Framework
    • 8.4.7.5 Reimbursement Scenario
  • 8.4.8 Rest Of Asia Pacific Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5 Latin America
  • 8.5.1 Latin America Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2 Brazil
    • 8.5.2.1 Key Country Dynamics
    • 8.5.2.2 Brazil Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2.3 Competitive/Market Scenario
    • 8.5.2.4 Regulatory Framework
    • 8.5.2.5 Reimbursement Scenario
  • 8.5.3 Argentina
    • 8.5.3.1 Key Country Dynamics
    • 8.5.3.2 Argentina Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3.3 Competitive/Market Scenario
    • 8.5.3.4 Regulatory Framework
    • 8.5.3.5 Reimbursement Scenario
  • 8.5.4 Rest Of Latin America Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.6 Middle East & Africa (MEA)
  • 8.6.1 Mea Endometriosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2 South Africa
    • 8.6.2.1 Key Country Dynamics
    • 8.6.2.2 South Africa Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2.3 Competitive/Market Scenario
    • 8.6.2.4 Regulatory Framework
    • 8.6.2.5 Reimbursement Scenario
  • 8.6.3 Saudi Arabia
    • 8.6.3.1 Key Country Dynamics
    • 8.6.3.2 Saudi Arabia Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3.3 Competitive/Market Scenario
    • 8.6.3.4 Regulatory Framework
    • 8.6.3.5 Reimbursement Scenario
  • 8.6.4 UAE
    • 8.6.4.1 Key Country Dynamics
    • 8.6.4.2 UAE Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4.3 Competitive/Market Scenario
    • 8.6.4.4 Regulatory Framework
    • 8.6.4.5 Reimbursement Scenario
  • 8.6.5 Kuwait
    • 8.6.5.1 Key Country Dynamics
    • 8.6.5.2 Kuwait Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5.3 Competitive/Market Scenario
    • 8.6.5.4 Regulatory Framework
    • 8.6.5.5 Reimbursement Scenario
  • 8.6.6. Rest of MEA Endometriosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

• 9.1 Participant Categorization
• 9.2 Participants' Overviews
• 9.3 Financial Performance
• 9.4 Product Benchmarking
• 9.5 Company Market Position Analysis
• 9.6 Company Profiles
  • 9.6.1 Bayer AG
    • 9.6.1.1 Company Overview
    • 9.6.1.2 Financial Performance
    • 9.6.1.3 Product Benchmarking
    • 9.6.1.4 Strategic Initiatives
  • 9.6.2 Pfizer, Inc.
    • 9.6.2.1 Company Overview
    • 9.6.2.2 Financial Performance
    • 9.6.2.3 Product Benchmarking
    • 9.6.2.4 Strategic Initiatives
  • 9.6.3 AbbVie, Inc
    • 9.6.3.1 Company Overview
    • 9.6.3.2 Financial Performance
    • 9.6.3.3 Product Benchmarking
    • 9.6.3.4 Strategic Initiatives
  • 9.6.4 AstraZeneca
    • 9.6.4.1 Company Overview
    • 9.6.4.2 Financial Performance
    • 9.6.4.3 Product Benchmarking
    • 9.6.4.4 Strategic Initiatives
  • 9.6.5 ObsEva SA
    • 9.6.5.1 Company Overview
    • 9.6.5.2 Financial Performance
    • 9.6.5.3 Product Benchmarking
    • 9.6.5.4 Strategic Initiatives
  • 9.6.6 Teva Pharmaceutical Industries Ltd.
    • 9.6.6.1 Company Overview
    • 9.6.6.2 Financial Performance
    • 9.6.6.3 Product Benchmarking
    • 9.6.6.4 Strategic Initiatives
  • 9.6.7 Teva Pharmaceutical Industries Ltd.
    • 9.6.7.1 Company Overview
    • 9.6.7.2 Financial performance
    • 9.6.7.3 Product Benchmarking
    • 9.6.7.4 Strategic Initiatives
  • 9.6.8 ELI LILLY AND COMPANY
    • 9.6.8.1 Company Overview
    • 9.6.8.2 Financial performance
    • 9.6.8.3 Product Benchmarking
    • 9.6.8.4 Strategic Initiatives
  • 9.6.9 Astellas Pharma, Inc.
    • 9.6.9.1 Company Overview
    • 9.6.9.2 Financial performance
    • 9.6.9.3 Product Benchmarking
    • 9.6.9.4 Strategic Initiatives
• 9.7 Strategy Mapping
  • 9.7.1 New Product Launches
  • 9.7.2 Acquisition
  • 9.7.3 Collaborations
  • 9.7.4 Partnerships
  • 9.7.5 Others (Clinical Trials, Campaign, Legal, And Pricing)

Chapter 10 Conclusion